Introduction
============

COPD is a common, preventable and treatable disease, characterized by persistent airflow limitation and respiratory symptoms, resulting in breathlessness and poor quality of life (QoL).[@b1-copd-13-2629] COPD continues to be a leading cause of morbidity and mortality globally, contributing to a substantial social and economic burden. The Global Burden of Disease Study, in 2010, ranked COPD as the fourth leading cause of death worldwide.[@b1-copd-13-2629]--[@b4-copd-13-2629] The global prevalence of COPD ranges from 7.6% to 8.9%.[@b5-copd-13-2629] In Japan, the prevalence is 8.6% in patients aged ≥40 years[@b6-copd-13-2629] and up to 10.3% in patients aged ≥60 years; the prevalence of COPD is 22% in patients with a history of smoking or respiratory symptoms.[@b7-copd-13-2629],[@b8-copd-13-2629]

There is a significant difference in clinical features of COPD patients between Asian countries and the rest of the world.[@b9-copd-13-2629] Higher age and low body mass index (BMI) are characteristic features of Japanese patients and have been reported as prognostic factors for various clinical outcomes of COPD.[@b10-copd-13-2629]--[@b15-copd-13-2629] It has been reported that COPD patients in Japan have fewer exacerbation frequencies, compared with other countries.[@b15-copd-13-2629],[@b16-copd-13-2629] An aging population and lower BMI are independent risk factors for morbidity and mortality in patients with COPD,[@b1-copd-13-2629],[@b17-copd-13-2629],[@b18-copd-13-2629] and these unique clinical features may emphasize the burden of COPD in Japan, compared with other countries.

COPD is generally perceived as a disease of old age; however, according to the cohort studies conducted in the USA, Europe and some Asian counties (other than Japan), it is estimated that approximately half of COPD patients are in the working age group (\<65 years of age) and employed.[@b19-copd-13-2629],[@b20-copd-13-2629] Patients with COPD not only have higher disability but also have a reduced QoL. High resource utilization leads to high medical expenditure in the national health care budget.[@b21-copd-13-2629] A study conducted by Polatli et al has reported higher medical costs associated with disease severity, higher COPD assessment test (CAT) score, COPD exacerbations and presence of comorbidities.[@b22-copd-13-2629] COPD patients have a higher chance of working fewer hours, of absenteeism and of poorer work performance.[@b23-copd-13-2629] The level of work impairment and productivity worsens with increasing age, disease severity and number of comorbidities.[@b24-copd-13-2629]

In Japan, the average annual cost per patient with moderate-to-severe COPD was estimated to be US\$9,893 in the Continuing to Confront COPD survey.[@b25-copd-13-2629] An earlier study by Katsura estimated the average annual cost per COPD patient in Japan to be US\$5,189.[@b21-copd-13-2629] The data from these studies, though different, highlight the high economic burden of COPD in Japan. Also, the information available on COPD burden in Japan is based mainly on the health care resource use. There is a paucity of data on the impact of COPD in terms of QoL, work activity impairment and productivity loss in Japan.[@b23-copd-13-2629] In an effort to inform health care policies and improve resource allocation, we aimed to describe the socioeconomic burden of COPD in Japan and the impact it may have on the working-age population.

Patients and methods
====================

Study design
------------

This was a 2-year retrospective chart review with cross-sectional patient-reported outcomes ([Figure 1](#f1-copd-13-2629){ref-type="fig"}). The study was conducted at 18 centers within Japan (9 clinics and 9 hospitals), where patients diagnosed with COPD are treated. The participating hospitals and clinics were selected based on geographical location, type of care (primary or secondary) and the population of the city/town where the site was located, in order to have a representative sample of COPD patients. Clinics were considered as primary care and hospitals as secondary.

This study was designed to capture the distribution of COPD severity among patients attending a physician's office within the defined age group and not the distribution of the patients with COPD in general in Japan.

The study was conducted in line with the principles of Declaration of Helsinki and the Ethical Guidelines for Epidemiological Research and was approved by the individual institutional review board for each trial center (Supplementary materials). The study is reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations.

Eligibility criteria
--------------------

The study enrolled patients diagnosed with COPD patients who were aged ≥40 years, current or ex-smokers, with at least one health care visit in the previous 12 months. Patients were included if they had a confirmed COPD diagnosis through spirometry and met the guidelines of the Japanese Respiratory Society (3rd edition of Japanese Respiratory Society Guidelines) criteria of having a postbronchodilator forced expiratory volume in 1 s (FEV~1~)/forced vital capacity (FVC) of \<70%, and the absence of other diseases that may lead to airflow obstruction. Patients' medical charts for a minimum of the previous 24 months, with information describing COPD treatment, consultations, hospitalizations and emergency hospital visits, were required to be available at the participating center.

Patients were excluded from the study if they had participated in any clinical trial at the time of study inclusion or in the previous 24 months, lack of reading and writing skills or severe cognitive impairment. As the study was retrospective, no patient withdrawal was expected. All patients who met the eligibility criteria and provided written informed consent were included in the study.

Data variables
--------------

Patient demographics and clinical characteristics were collected. Disease characteristics including COPD severity as per GOLD strategy;[@b26-copd-13-2629] disease prognosis by the BMI, obstruction, dyspnea and exercise capacity (BODE) index; exacerbation history, including number and severity of exacerbations; COPD treatments received and degree of dyspnea as assessed by modified Medical Research Council (mMRC) dyspnea scale were also collected. Moderate exacerbations were defined as worsening of COPD symptoms that required consultation with primary care physician to provide change in treatment (eg, a prescription of steroid), and severe exacerbations were defined as worsening of symptoms resulting in hospitalization.

COPD symptoms were assessed by the CAT score that measured the impact of COPD on a patient's life, with higher scores indicating a higher impact. Additionally, the COPD AM symptom questionnaire assessed symptoms that were worse in the morning, their duration and their impact on the rest of the day.

Health-related quality of life (HRQoL) was measured using the EuroQoL Group 5 Dimension (EQ-5D-5L) questionnaire, which has two parts: 1) descriptive system with five questions, assessing five components -- "mobility", "self-care", "usual activities", "pain/discomfort" and "anxiety/depression" and 2) a visual analogue scale (VAS), describing the patient's health state on a scale from 0 (worst imaginable state) to 100 (best imaginable state) (EQ-5D-5L Questionnaire). The EQ-5D-5L health states, derived from the above descriptive system, can be converted to single index values and are presented in country-specific value sets. The index-based scores range from 0 to 1 in the Japanese population,[@b27-copd-13-2629],[@b28-copd-13-2629] where 0 indicates death and 1 indicates perfect health.

Impact on work productivity was assessed by the work productivity and activity impairment general health (WPAI-GH) questionnaire, which evaluates the effect of general health problems on productivity losses through six questions related to the working situation. For this study, the word "health problems" in the questionnaire was replaced with "COPD". The questionnaire was administered to all enrolled patients aged ≤70 years to analyze work productivity in the group of working patients aged \<65 years and 65--70 years. The outcomes from the WPAI-GH questionnaire were expressed as percentage of impairment, with higher numbers indicating greater impairment and lower productivity. These outcomes relate to 7 days prior to administration of questionnaire.[@b29-copd-13-2629],[@b30-copd-13-2629]

Data on health care utilization due to COPD and comorbidities were collected during the 2-year review period and included hospitalization episodes, emergency services, consultations with health care providers and pulmonary rehabilitation. Total direct medical costs associated with COPD and comorbidities were calculated from the payer perspective at the national level. For hospitalization and other resources, unit costs were defined according to diagnosis-related group (DRG) listing. Unit costs for drugs were set at the price of the cheapest drug in the category, and unit costs were applied to the corresponding health care resources based on DRG list to obtain cost estimation.

Data collection and handling
----------------------------

The study was non-interventional; therefore, a therapy protocol, diagnostic/therapeutic procedure or a visit schedule was not imposed. Patients were treated as per routine medical practice according to the local prescribing information. The study was conducted in a cross-sectional fashion; the investigating physician collected the sociodemographic details (age, gender, BMI, smoking history and employment status), clinical data (duration of COPD, severity, comorbidities, ongoing COPD treatment and exacerbation history) and health care utilization data (hospitalization episodes, emergency services, consultation with health care providers and pulmonary rehabilitation) that were registered on each patient's medical chart and recorded in an electronic Case Report Form (e-CRF) that had been especially designed for the study. At the time of routine visit, patients were asked to complete the paper-based questionnaires on patient-reported outcomes and work productivity (CAT questionnaire, EQ-5D questionnaire and WPAI-GH questionnaire) in their local language. The completed questionnaires were then transferred to the local contract research organization (CRO).

Statistical analysis
--------------------

The study results were described according to age groups (\<65 years and ≥65 years), and the study was not powered to compare the two age groups. The sample size was calculated to have a precise estimate of the mean percentage of time of absenteeism in patients aged \<65 years and the burden of COPD in patients aged ≥65 years. Considering these, and based on the previous international survey on COPD,[@b24-copd-13-2629] enrollment of a minimum of 154 patients in the \<65 age group would allow estimation of the mean % time of absenteeism with a precision of 3.7 SD, and 151 patients in the older age group would allow estimation of the COPD burden with a precision of 0.16 SD. However, 71 patients were recruited in the \<65-year age group, and the precision of study result was estimated to be between 5.4 and 5.5 points for this group.

Continuous variables were described by means of descriptive statistics, median and interquartile range and calculated for non-normally distributed data; categorical variables were described by frequencies and respective percentages. The study population was analyzed in terms of sociodemographic and clinical variables to describe the profile of COPD patients in Japan in each age subgroup. All costs were reported in Japanese yen (¥) and US dollars (US\$), exchange rate as at 2015 ¥1 = US\$0.01. Statistical analysis was performed using Statistical Analysis Software (SAS) ver. 9.3 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Patient demographics
--------------------

Based on the sample size calculation, it was expected that at least 305 patients would be enrolled in the study; however, in total, 222 patients were enrolled (71 patients aged \<65 years; 151 aged ≥65 years, 151). Demographics and baseline characteristics are presented in [Table 1](#t1-copd-13-2629){ref-type="table"}. In both age subgroups, most patients were men, ex-smokers and had moderate or severe airflow limitation. The most frequently reported comorbidities in both age groups were hypertension, hyperdyslipidemia and other lung conditions. Asthma was the most frequent comorbidity among other lung conditions and was reported in 14 and 23 patients in the \<65-year and ≥65-year age groups, respectively.

Disease and treatment characteristics
-------------------------------------

The risk of dying due to respiratory causes, as calculated by the BODE index, was greater in patients aged ≥65 years at the time of study visit ([Table 2](#t2-copd-13-2629){ref-type="table"}). During the 2-year reference period, long-acting muscarinic antagonists (LAMAs) were prescribed more frequently in patients aged ≥65 years, while patients aged \<65 years were treated mostly with long-acting β~2~-agonist (LABA) combinations ([Table 2](#t2-copd-13-2629){ref-type="table"}). The annual number of exacerbations was comparable between the age groups, with most patients in both age groups experiencing moderate exacerbations. The number of patients experiencing severe exacerbations was slightly higher in the ≥65-year age group ([Table 2](#t2-copd-13-2629){ref-type="table"}).

At the time of study visit, the mean±SD CAT score for patients in the \<65-year age group and the ≥65-year age group was 11.38±8.57 points and 13.66±8.26 points, respectively. A total of 37 patients (52.1%) in the \<65-year age group and 95 patients (62.9%) in the ≥65-year age group had a CAT score of ≥10 points, indicating a high impact of COPD on patients' lives. In patients aged \<65 years, the most frequent symptoms reported in the morning were shortness of breath (35.2%) and cough and coughing up phlegm (19.7%), while for patients in the ≥65-year group, the most frequently observed symptoms were coughing up phlegm (37.1%) and shortness of breath (36.4%). Assessments based on the COPD AM symptom questionnaire are highlighted in [Table 3](#t3-copd-13-2629){ref-type="table"}.

HRQoL
-----

"Mobility" and "usual activities" were the most affected dimensions from the EQ-5D-5L questionnaire in the \<65-year group, with 43.7% patients reporting problems in walking about and doing their usual activities; in the ≥65-year age group, "mobility" was most affected, with 56.3% of patients reporting problems in walking ([Table 4](#t4-copd-13-2629){ref-type="table"}). The mean VAS score was 70.51 (SD, 23.80) points for patients in the \<65-year age group and 69.17 (SD, 18.72) points in the ≥65-year age group. The mean EQ-5D-5L index value for patients in the \<65-year age group was 0.79 (SD, 0.22) and 0.77 (SD, 0.18) for patients in the ≥65-year age group.

Health care utilization
-----------------------

During the 2-year retrospective period, 12.7% patients were hospitalized in the \<65-year age group (mean±SD episodes 1.67±1.66); 8.4% patients had emergency room visits and 4.2% attended pulmonary rehabilitation programs (mean duration 72.00±25.63 weeks). In the ≥65-year age group, 12.6% were hospitalized during the 2-year study period (mean±SD hospitalization episodes 1.79±1.32); 6.6% patients had emergency room visits, and 10.6% attended pulmonary rehabilitation programs (mean duration 77.63±78.22 weeks). The mean±SD duration of hospital stay upon hospitalization (days per patient) was 16.67±13.84 and 18.03±12.40 in the \<65-year and ≥65-year age groups, respectively. Estimated annual costs of health care resources associated with COPD are presented in [Figure 2](#f2-copd-13-2629){ref-type="fig"} for both age groups. The mean±SD annual costs per patient in the younger and older age groups were ¥438,975.8±534,379.0 (US\$4,389.8±5,343.8) and ¥467,871.6±606,121.1 (US\$4,678.7±6,061.2), respectively, with pharmacological treatment being the main driver of health care-related costs in both cohorts.

According to the number of comorbidities, the estimated annual cost of health care resources related to COPD, in patients aged \<65 years, with no comorbidities, was ¥379,060.8±414,781.5 (US\$3,790.6±4,147.8); the respective cost in the ≥65-year age group (no comorbidity) was ¥159,799.2±121,764.7 (US\$1,598.0±1,217.6). The corresponding costs were ¥481,686.3±419,062.0 (US\$4,816.9±4,190.6) and ¥844,080.7±723,440.4 (US\$8,440.8±7,234.4), respectively, for patients with three additional comorbidities. Health care resources not related to COPD, due to comorbidities, were also high and comparable in both age groups.

In the \<65-year age group, eight patients (11.3%) were hospitalized due to comorbidities, with annual mean±SD number of hospitalization episodes of 0.94±0.73, and annual mean length of stay of 5.03±3.23 days; a total of four patients (5.6%) had emergency room visits with annual mean visits of 1.38±1.75. Sixteen patients (10.6%) in the ≥65-year age group were hospitalized due to comorbidities, the annual incidence of hospitalization was 0.81±0.54 times with a stay duration of 3.25±2.20 days; seven patients (4.6%) were treated in the emergency room with 0.64±0.38 mean annual visits. The annual costs of health care resources not related to COPD are presented in [Table 5](#t5-copd-13-2629){ref-type="table"} for both the age groups.

Work productivity
-----------------

A total of 62.9% of patients in the younger age group and 23.3% in the ≥65-year age group were working for pay, according to the WPAI-GH questionnaire. Mean percentage of work and daily activity impairment in both age groups are highlighted in [Figure 3](#f3-copd-13-2629){ref-type="fig"}. The mean ± SD cost of productivity loss was estimated to be ¥5,287,024.3±3,763,540.3 (US\$52,870.2±37,635.4) in patients aged \<65 years and ¥3,018,974.4±2,480,179.2 (US\$30,187.4±24,799.8) in those aged ≥65 years. These data show a considerable impact of COPD on productivity loss in the working-age population. In both age groups, there was an increase in work impairment and in the number of exacerbations; however, none of the WPAI results achieved statistical significance ([Table 6](#t6-copd-13-2629){ref-type="table"}).

COPD symptoms also caused impairment during working hours, and overall and activity impairment. Work productivity, based on CAT score, was evaluated in both age groups with COPD. In patients aged \<65 years, the impairment during working hours was significantly higher (*P* \< 0.001) in patients with CAT score of ≥10 points versus those with CAT score \<10 points. The overall work and activity impairment was also significantly higher (both *P* \< 0.001) for patients with CAT scores ≥10 points ([Table 7](#t7-copd-13-2629){ref-type="table"}). In patients aged ≥65 years, the activity impairment due to COPD was significantly higher (*P* \< 0.001), while other work productivity parameters were numerically higher in patients with CAT scores ≥10 points ([Table 7](#t7-copd-13-2629){ref-type="table"}).

Discussion
==========

The objective of this observational study was to assess the socioeconomic burden of COPD in Japan and its impact on the working-age population (aged \<65 years). The study also involved patients aged ≥65 years in order to understand the overall economic and societal impact of COPD. The study was not powered for comparison between the two age groups. The study was conducted through retrospective chart reviews of patient data, compared with another similar study conducted in six different countries through a subjective and retrospective survey,[@b24-copd-13-2629] which may have had a greater risk of either under- or over-reporting of outcomes. Patients who attended the participant site during the study data collection period were invited to participate in the study and those who provided informed consent were included. It is possible that more severely affected patients in worse health condition chose to participate in the study in anticipation that it would result in better care from their treating physician. Selection bias could possibly have led to low recruitment in the younger population (aged \<65 years) creating a vast imbalance in the ratio of patients enrolled in the two age groups, as patients in the ≥65-years age group are more prone to worsened health conditions.

Another possible reason for the lower-than-expected enrollment of \<65-year-old patients in contrast to the elder (≥65 years of age) population might be that the average age of patients diagnosed with COPD in Japan is higher than in other countries, especially Western countries; the average age of patients with COPD in Japan is reported to be around 70 years, as revealed in several cohort studies conducted in Japan.[@b13-copd-13-2629]--[@b15-copd-13-2629] This difference in age has also been observed in the demographic information in large clinical trials.[@b31-copd-13-2629]

In both age subgroups, the majority of patients were male, which, in line with other observational studies in Japan,[@b8-copd-13-2629],[@b32-copd-13-2629],[@b33-copd-13-2629] reflects a higher prevalence of COPD in Japanese males. A higher proportion of patients had moderate or severe airflow limitation in both age groups; the number of patients with severe exacerbation was slightly higher in the ≥65-year age group. Most COPD patients experienced at least one comorbidity, with a higher proportion across both age groups suffering from diseases of the cardiovascular system and diabetes. Asthma was also reported as comorbidity in both age groups. It is well known that a differential diagnosis of asthma from COPD is clinically difficult at times, which may lead to an overlap of these disorders. In some patients with chronic asthma, a distinct diagnosis of COPD is not possible even using the current physiological testing and imaging techniques, and it is possible that asthma and COPD may coexist.[@b1-copd-13-2629],[@b34-copd-13-2629]

More than half of patients (58%) in the \<65-year age group were working for pay, compared with 18% in the ≥65-year age group. This is in contrast to the data from a patient survey conducted in several countries, which revealed that 45% of Japanese patients with COPD were working at the time of the survey.[@b35-copd-13-2629] In each of the age cohorts, more than half of patients had a CAT score ≥10, indicating a high impact of COPD on patients' HRQoL. This was in line with a population-based survey in Japan that revealed a mean CAT score of 16 points -- similar to that observed in this study.[@b35-copd-13-2629] Earlier studies have shown a strong correlation with the CAT questionnaire with severity of airflow obstruction, dyspnea and comorbidities in Japanese patients.[@b13-copd-13-2629],[@b36-copd-13-2629] Overall, these data show that COPD symptomatology remains an important factor on impairment of HRQoL.

In this study, EQ-5D-5L a preference-based generic questionnaire, was used to evaluate HRQoL in enrolled patients. A meta-analysis by Pickard et al[@b37-copd-13-2629] showed that lower EQ-5D-5L index scores were associated with more severe GOLD stage. In our study, the index scores were comparable between the \<65-year and the ≥65-year age groups (0.79 and 0.77, respectively), where a lower index score might have been expected in the older age group. The comparable index scores in both age groups in our study may be due to the lower proportion of very severe (GOLD grade IV) patients in the ≥65-year age group (9.8%), compared with the younger group (13.5%).

Work and activity impairment was found to be significantly higher in patients aged \<65 years, with a greater impact on HRQoL (higher CAT score), while patients aged ≥65 years had greater activity impairment with a higher CAT score. To the best of our knowledge, this was the first study that correlated work activities to CAT scores, confirming that work activities are more affected in patients with reduced HRQoL. Almost 6% of patients in both age groups (four patients aged \<65 years and nine patients aged ≥65 years) retired due to COPD. The proportion of patients retiring due to COPD observed in this study was lower when compared with that (18%) of a similar study conducted in six different countries,[@b24-copd-13-2629] which may implicate the difference of COPD burden in Japan compared with other countries, although we cannot directly compare the two studies due to differences in demographic composition. There was a considerable impact of COPD on productivity loss in the working-age population, which was evident from the costs incurred due to productivity loss. Indirect costs associated with COPD are significant; in the US, the indirect costs for COPD patients accounted for 27%--61% of the total medical costs, depending on the population studied, while in Greece, it accounted for 37.5% of the annual medical cost for COPD patients.[@b38-copd-13-2629],[@b39-copd-13-2629] Although the indirect costs were estimated considering only the productivity loss, the number of patients retiring due to COPD highlights a considerable economic impact of the disease in Japan.

The annualized rate of hospitalizations was \~12% during the study, which was considerably higher than the 5% reported in the Continuing to Confront COPD International Patient Survey 2012--2013; however, emergency room visits in our study (8.4% in \<65-year group and 6.6% in ≥65-year group) were comparable with the patient survey (9%). Differences in the study methodology should be considered when comparing results from the two studies. Another aspect to be considered is while the Continuing to Confront COPD International Patient Survey 2012--2013 survey included patients with physician-diagnosed COPD, emphysema or chronic bronchitis,[@b35-copd-13-2629] our chart review study included only patients with physician-diagnosed COPD confirmed through spirometry. In our study, the mean hospitalization stay for COPD was 16.67 days in the \<65-year and 18.03 days in the ≥65-year age groups. The annual mean direct medical cost per patient due to COPD was ¥349,080 as estimated in a model by Nishimura and Zaher;[@b40-copd-13-2629] there was a small increase in mean annual costs in this study, ranging from ¥438,975.82 to ¥467,871.56. This Japan-based study not only confirmed the above findings but also showed that the annual cost of managing COPD patients (considering only the health care resources used due to COPD) increases when the number of comorbidities increases; however, the study was not powered to validate this association.

Limitations
-----------

Clinical-chart data had to be available for all patients at the participating sites. Despite follow-up of patients at participating sites, information on the clinical charts may have been incomplete. Another limitation was related to the sample size estimation as the study was not powered to allow for disease stratification or comparison between the age groups. Results from this non-interventional study can be extrapolated to the Japanese population with COPD within the age groups defined in the study, who were regularly attending their physician.

Conclusion
==========

Overall, COPD presents a significant socioeconomic burden in Japan. It remains an important driver of HRQoL impairment and work and activity impairment among Japanese patients. The management of COPD contributes substantially to the cost of health care resources. A considerable impact was observed on patients of working age (\<65 years), which augment the overall disease burden. These findings may inform future COPD health care initiatives in Japan.

Supplementary materials
=======================

Institutional review board approval
-----------------------------------

The protocol for this study was approved by the individual institutional review board (IRB) for each trial center. These trial centers (all based in Japan) are the following:

  Sr. no   Participating trial center
  -------- --------------------------------------------------------------------------------------
  1        Rumoi City Hospital, 2-16-1, Shinonomecho, Rumoi, Hokkaido
  2        KKR Sapporo Medical Center, 6-30-40, Hiragishiichijo, Toyohira-ku, Sapporo, Hokkaido
  3        Tohno Chuo Clinic, 1-14-1, Matsugasecho, Mizunami, Gifu
  4        Fujisawa City Hospital, 2-6-1, Fujisawa, Fujisawa, Kanagawa
  5        Higuchi Clinic, 261-3, Agehari, Kakegawa, Shizuoka
  6        Kawarada Clinic, 1-81-1, Sohri, Kasuga, Fukuoka
  7        Okubo Clinic, 1-19-18, Marunouchi, Kohfu, Yamanashi
  8        Senzoku Respiratory Allergy Clinic, 1-1-6, Senzoku, Ohta-ku, Tokyo
  9        Okano Clinic, 7-2, Akayamahoncho, Koshigaya, Saitama
  10       Tsuchiya Clinic, 2-1-1, Tonyamachi, Takasaki, Gunma
  11       Hanzomon Hospital, 1-10, Kohjimachi, Chiyoda-ku, Tokyo
  12       Takahashi Naika Clinic, 6-2-6, Higashikoigakubo, Kokubunji, Tokyo
  13       Japanese Red Cross Takayama Hospital, 3-11, Tenmamachi, Takayama, Gifu
  14       Komatsu Municipal Hospital, 60 Ho, Mukaimotoorimachi, Komatsu, Ishikawa
  15       Toyama City Hospital, 2-1, Imaizumihokubumachi, Toyama, Toyama
  16       Shinjo Clinic, 2-23-10, Arakawa, Toyama, Toyama
  17       Toyama Prefectural Central Hospital, 2-20-78, Nishinagae, Toyama, Toyama
  18       Saiseikai Kanazawa Hospital, 2-13-6, Akatsuchimachi, Kanazawa, Ishikawa
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  \(b\) An informative and balanced summary of what was done and what was found is provided in the abstract                                                            
  **Introduction**                                                                                                                                                     
  Background/rationale                                                                                        2                                                        Explained the scientific background and rationale for the investigation being reported
  Objectives                                                                                                  3                                                        Stated specific objectives, no prespecified hypotheses defined for this study
  **Methods**                                                                                                                                                          
  Study design                                                                                                4                                                        Key elements of study design presented early in the paper
  Setting                                                                                                     5                                                        Described the setting, locations and data collection
  Participants                                                                                                6                                                        Included the eligibility criteria and the sources and methods of selection of participants
  Variables                                                                                                   7                                                        Clearly defined all outcomes
  Data sources/measurement                                                                                    8                                                        For each variable of interest, provided sources of data and details of methods of assessment (measurement)
  Bias                                                                                                        9                                                        Described potential selection bias
  Study size                                                                                                  10                                                       Explained study size calculation
  Categorical variables                                                                                       11                                                       Explain how variables were handled in the analyses; quantitative variables not applicable
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  Participants                                                                                                13                                                       Reported numbers of individuals at each stage of study -- numbers required for study, included in the study and analyzed
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  Indicated number of participants with missing data for each variable of interest                                                                                     
  15                                                                                                          Reported numbers of outcome events or summary measures   
  Main results                                                                                                16                                                       Provided estimates and statistical significance
  Other analyses                                                                                              17                                                       Report other analyses done -- eg, analyses of subgroups and interactions and sensitivity analyses -- not applicable
  **Discussion**                                                                                                                                                       
  Key results                                                                                                 18                                                       Summarized key results with reference to study objectives
  Limitations                                                                                                 19                                                       Discussed limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
  Interpretation                                                                                              20                                                       Included a cautious overall interpretation of results considering objectives, limitations
  Generalizability                                                                                            21                                                       Discussed the generalizability (external validity) of the study results
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  Funding                                                                                                     22                                                       Provided the source of funding for the present study
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###### 

Patient demographics and baseline characteristics

  Variables                                                                         Aged \<65 years   Aged ≥65 years
  --------------------------------------------------------------------------------- ----------------- ----------------
  Gender, n (%) (N′ = 71, 151)                                                                        
   Male                                                                             60 (84.5)         144 (95.4)
   Female                                                                           11 (15.5)         7 (4.6)
  Age (years) (N′ = 71, 151)                                                        60.49±5.27        75.22±5.88
  BMI (kg/m^2^) (N′ = 70, 150)                                                      21.65±3.47        21.87±3.40
  Smoking status, n (%) (N′ = 71, 151)                                                                
   Current smoker                                                                   17 (23.9)         25 (16.6)
   Ex-smoker                                                                        54 (76.1)         126 (83.4)
  Number of pack-years (N′ = 45, 102)                                               52.41±29.43       69.54±35.42
  Time since COPD diagnosis (years) (N′ = 70, 150)                                  6.07±4.17         5.97±3.44
  Employment status, n (%) (N′ = 69, 145)                                                             
   Working                                                                          40 (58.0)         26 (18.0)
   Retired                                                                          21 (30.4)         96 (66.2)
    Due to COPD                                                                     4 (5.8)           9 (6.2)
  Comorbidities,[a](#tfn2-copd-13-2629){ref-type="table-fn"} n (%) (N′ = 71, 151)                     
   Hypertension                                                                     18 (25.4)         68 (45.0)
   Other lung disease                                                               20 (28.2)         38 (25.2)
    Asthma                                                                          14 (19.7)         23 (15.2)
    Emphysema                                                                       3 (4.2)           6 (4.0)
   Hyperdyslipidemia                                                                12 (16.9)         40 (26.5)
  Charlson comorbidity score (points) (N′ = 52, 125)                                4.71±1.84         5.57±1.40

**Notes:** N′ is the total number of patients evaluated for each parameter. Data are presented as mean±SD, unless otherwise stated.

Data given for most frequent observed comorbidities in both the age groups.

**Abbreviation:** BMI, body mass index.

###### 

Disease characteristics

  Disease characteristics                                 Aged \<65 years   Aged ≥65 years
  ------------------------------------------------------- ----------------- ----------------
  Postbronchodilator FEV~1~, % predicted (N′ = 52, 122)   56.98±21.51       55.99±20.51
  Postbronchodilator FEV~1~/FVC, L (N′ = 52, 122)         0.54±0.12         0.53±0.15
  Severity of airflow limitation, n (%) (N′ = 52, 122)                      
   Mild (FEV~1~ ≥80% predicted)                           10 (19.2)         10 (8.2)
   Moderate (50% ≤ FEV~1~ \<80% predicted)                21 (40.4)         62 (50.8)
   Severe (30% ≤ FEV~1~ \<50% predicted)                  14 (26.9)         38 (31.1)
   Very severe (FEV~1~ \<30% predicted)                   7 (13.5)          12 (9.8)
  COPD prognosis (BODE index) (N′ = 71, 151)              0.90±0.97         1.20±1.15
  COPD treatment received, n (%) (N′ = 71, 150)                             
   SABA                                                   1 (1.4)           4 (2.6)
   LABA                                                   20 (28.2)         68 (45.0)
   LAMA                                                   48 (67.6)         111 (74.0)
   ICS                                                    15 (21.1)         25 (16.7)
   Methylxanthines                                        28 (39.4)         57 (38.0)
   LABA in combinations                                   54 (76.1)         91 (60.7)
   Others                                                 33 (46.5)         59 (39.3)
  Oxygen therapy, n (%) (N′ = 71, 151)                    7 (9.9)           26 (17.2)
   NPPV                                                   6 (8.4)           21 (13.9)
   IPPV                                                   1 (1.4)           5 (3.3)
  Patients with exacerbations, n (%) (N′ = 71, 151)       27 (38.0)         50 (33.1)
   Moderate                                               26 (36.6)         43 (28.5)
   Severe                                                 6 (8.4)           15 (9.9)
  Annual number of exacerbation (N′ = 71, 151)            1.11±0.96         1.15±0.76

**Notes:** N′ is the total number of patients evaluated for each parameter. Data are presented as mean±SD, unless otherwise stated.

**Abbreviations:** BMI, body mass index; BODE, BMI, obstruction, dyspnea and exercise capacity; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroids; IPPV, invasive positive-pressure ventilation; LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic antagonists; NPPV, non-invasive positive-pressure ventilation; SABA, short-acting β~2~-agonist.

###### 

Responses in COPD AM symptom questionnaire according to age groups

  COPD AM symptom questionnaire assessment                Aged \<65 years   Aged ≥65 years
  ------------------------------------------------------- ----------------- ----------------
  COPD symptoms the patients feel worse in the mornings   N′ = 71           N′ = 151
   Shortness of breath                                    25 (35.2)         55 (36.4)
   Cough                                                  14 (19.7)         35 (23.2)
   Coughing up phlegm                                     14 (19.7)         56 (37.1)
   Wheezing                                               6 (8.5)           19 (12.6)
   Chest tightness                                        3 (4.2)           9 (6.0)
   Other                                                  16 (22.5)         23 (15.2)
  Duration of COPD symptoms from wake up in morning       N′ = 41           N′ = 99
   A few minutes                                          29 (70.7)         59 (59.6)
   Up to half an hour                                     5 (12.2)          17 (17.2)
   Between half an hour and an hour                       2 (4.9)           5 (5.0)
   Between 1 and 2 h                                      3 (7.3)           3 (3.0)
   Between 2 and 3 h                                      1 (2.4)           7 (7.1)
   More than 3 hours                                      1 (2.4)           8 (8.1)
  Impact of worse COPD symptoms on rest of the day        N′ = 48           N′ = 111
   No                                                     39 (81.3)         78 (70.3)

**Notes:** N′ is the total number of patients evaluated for each parameter. Data are presented as n (%).

###### 

EQ-5D-5L dimensions in \<65-year and ≥65-year age groups

  -------------------------------------------------------------------------------------------
  EQ-5D-5L dimensions                                    Aged \<65 years\   Aged ≥65 years\
                                                         (N′ = 71)          (N′ = 151)
  ------------------------------------------------------ ------------------ -----------------
  Mobility                                                                  

   I have no problems in walking about                   40 (56.3)          66 (43.7)

   I have slight problems in walking about               16 (22.5)          41 (27.2)

   I have moderate problems in walking about             8 (11.3)           22 (14.6)

   I have severe problems in walking about               5 (7.0)            20 (13.2)

   I am unable to walk about                             2 (2.8)            2 (1.3)

   Valid n                                               71 (100.0)         151 (100.0)

  Self-care                                                                 

   I have no problems washing or dressing myself         54 (76.1)          111 (73.5)

   I have slight problems washing or dressing myself     8 (11.3)           20 (13.2)

   I have moderate problems washing or dressing myself   5 (7.0)            11 (7.3)

   I have severe problems washing or dressing myself     3 (4.2)            9 (6.0)

   I am unable to wash or dress myself                   1 (1.4)            0

   Valid n                                               71 (100.0)         151 (100.0)

  Usual activities                                                          

    have no problems doing my usual activities           40 (56.3)          80 (53.3)

   I have slight problems doing my usual activities      19 (26.8)          34 (22.7)

   I have moderate problems doing my usual activities    5 (7.0)            24 (16.0)

   I have severe problems doing my usual activities      7 (9.9)            12 (8.0)

   I am unable to do my usual activities                 0                  0

   Valid n                                               71 (100.0)         150 (99.3)

  Pain/discomfort                                                           

   I have no pain or discomfort                          49 (70.0)          94 (62.3)

   I have slight pain or discomfort                      14 (20.0)          36 (23.8)

   I have moderate pain or discomfort                    3 (4.3)            17 (11.3)

   I have severe pain or discomfort                      3 (4.3)            3 (2.0)

   I have extreme pain or discomfort                     1 (1.4)            1 (0.7)

   Valid n                                               70 (98.6)          151 (100.0)

  Anxiety/depression                                                        

   I am not anxious or depressed                         43 (61.4)          98 (64.9)

   I am slightly anxious or depressed                    17 (24.3)          40 (26.5)

   I am moderately anxious or depressed                  5 (7.1)            10 (6.6)

   I am severely anxious or depressed                    4 (5.7)            3 (2.0)

   I am extremely anxious or depressed                   1 (1.4)            0

   Valid n                                               70 (98.6)          151 (100.0)
  -------------------------------------------------------------------------------------------

**Note:** Data are presented as n (%).

**Abbreviation:** EQ-5D-5L, EuroQoL Group 5 Dimension.

###### 

Health care resources utilization cost not related to COPD

  Annual costs               Aged \<65 years (N = 71)                     Aged ≥65 years (N = 151)
  -------------------------- -------------------------------------------- --------------------------------------
  Hospitalization episodes   ¥198,775.6±318,858.6 (US\$1,987.8±3,188.6)   ¥84,969.3±73,633.8 (US\$849.7±736.3)
  Emergency room visits      ¥17,875.0±22,750.0 (US\$178.8±227.5)         ¥8,357.1±4,913.5 (US\$83.6±49.1)

**Note:** Data are presented as mean±SD.

###### 

WPAI results according to number of exacerbations

  WPAI assessment              Patients with exacerbations   *P*-value                                               
  ---------------------------- ----------------------------- ------------- ------------- ------------- ------------- -------
  Patients aged \<65 years                                                                                           
   % absenteeism               4.27±19.65                    6.67±16.33    2.16±4.83     30.30±52.49   0.00±0.00     0.691
  \% presenteeism              15.77±24.19                   35.00±29.50   22.00±43.82   33.33±41.63   0.00±0.00     0.317
   % overall work impairment   16.53±24.79                   41.00±26.94   22.00±43.82   57.58±50.27   0.00±0.00     0.185
   % activity impairment       22.56±29.53                   20.00±25.30   20.00±36.97   48.33±47.50   40.00±56.57   0.744
  Patients aged ≥65 years                                                                                            
   % absenteeism               1.69±5.53                     0.31±0.82     0.00±1.00     22.33±33.00   0.00±1.00     0.584
  \% presenteeism              24.61±31.78                   14.28±29.36   0.00±1.00     0.00±1.00     0.00±1.00     0.369
   % overall work impairment   25.23±32.41                   14.35±29.52   0.00±1.00     0.00±1.00     0.00±1.00     0.290
   % activity impairment       28.09±28.17                   24.44±25.72   13.33±23.45   54.28±41.57   30.00±26.18   0.179

**Notes:** Data are presented as mean±SD. Absenteeism, work time missed due to health problems; presenteeism, impairment at work/reduced on-job effectiveness due to health problems; WPAI, work productivity and activity impairment.

###### 

WPAI results according to CAT score

  WPAI assessment              Patients with CAT score \<10   Patients with CAT score ≥10   *P*-value
  ---------------------------- ------------------------------ ----------------------------- -----------
  Patients aged \<65 years                                                                  
   % absenteeism               1.90±8.73                      10.64±29.24                   0.142
   % presenteeism              3.64±7.27                      39.47±32.23                   \<0.001
   % overall work impairment   5.52±11.78                     43.48±34.21                   \<0.001
   % activity impairment       2.81±5.81                      43.51±33.60                   \<0.001
  Patients aged ≥65 years                                                                   
   % absenteeism               0.00±1.00                      5.06±13.09                    0.059
   % presenteeism              3.63±5.04                      29.23±35.46                   0.119
   % overall work impairment   3.63±5.04                      29.88±35.99                   0.081
   % activity impairment       10.00±14.85                    40.00±29.62                   \<0.001

**Notes:** Data are presented as mean±SD. Absenteeism, work time missed due to health problems, presenteeism, impairment at work/reduced on-job effectiveness due to health problems.

**Abbreviations:** CAT, COPD assessment test; WPAI, work productivity and activity impairment.
